Chardan Capital Markets

Chardan: R1 RCM Will Make A Full Recovery

Expect More Downside In Axovant Sciences

Straight Path Crossed: Speculative Short To M&A Darling, A Look Back At StraightPath Communications Journey

Expect More Downside In Axovant Sciences

Straight Path Crossed: Speculative Short To M&A Darling, A Look Back At StraightPath Communications Journey

Did Globalstar Deserve To Move Higher On Straight Path Takeover News?

4 Reasons Why 2017 Will Be A Pivotal Year For Vuzix

Did Globalstar Deserve To Move Higher On Straight Path Takeover News?

4 Reasons Why 2017 Will Be A Pivotal Year For Vuzix

AveXis Offers Easily The Best Treatment Option For SMA Type-1 Patients

Vuzix's Accelerated Sales Ramp Should Continue In 2017

Chardan Capital Markets Recent News

Clovis Shares Reiterated As A Sell Following 10% Rally

Chardan Analyst Suggests An AveXis-Ionis Pair Trade

Social Reality Wins A Buy Rating, $9 Price Target From Chardan

Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April

Despite Guidance Miss, Teladoc Still Attractive

5 Key Takeaways In Regeneron's Praluent Suit, Steps Forward

The Medicines Co. Is A Top Pick For 2017

Reasons To Stay Bullish On Alnylam In The New Year

For Arbutus' Hepatitis B Treatment, 'Liver Safety Risk Overwhelms Promising Efficacy'

Chardan Upgrades Regeneron; Cites Fovista Failure, Stock's Recent Underperformance

Chardan Downgrades Ophthotech As Fovista Fails Phase III Trials For Wet AMD

4 Possible Catalysts On Eyegate's Horizon

Chardan: Watch Wearable Maker Vuzix Into CES

Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space

WageWorks Shares Could Rise 16% Over Next Year

Arrowhead Pharma Downgraded Following EX-1 RNAi Program Discontinuations

Amicus Therapeutics: Here's The Good News

Teladoc Shares Could Rise 40% Over The Next Year

Chardan Recommends Selling Clovis Oncology

Novartis A Buy At Chardan

3 Turnaround Stories Getting Love From Sell-Side Analysts

Chardan Analyst Believe iPass' Turnaround Strategy Is Working

Weak Competition, Favorable Regulatory Environment Among Tailwinds For Sunworks